Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377142 | 1.00 | LMNA (0.48) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL14495177 | 1.00 | LMNA (0.48) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL23588703 | 0.84 | LMNA (0.37) | LMNACYP2C9 | |
| SCHEMBL11036944 | 0.80 | LMNA (0.57) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL6745315 | 0.76 | — | — | |
| SCHEMBL17427862 | 0.73 | — | — | |
| SCHEMBL20206665 | 0.72 | LMNA (0.43) | LMNACYP2C9 | |
| SCHEMBL14161808 | 0.70 | LMNA (0.46) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL23588970 | 0.70 | LMNA (0.46) | LMNACYP2C9CHRM2CHRM1CHRM3 | |
| SCHEMBL14175783 | 0.70 | LMNA (0.46) | LMNACYP2C9CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | LMNA 233/4885CYP2C9 4407/4885CHRM2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.